High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
12
08
2021
revised:
16
09
2021
accepted:
08
11
2021
pubmed:
19
11
2021
medline:
9
3
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54). A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.
Sections du résumé
BACKGROUND
There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects.
METHODS
This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data.
RESULTS
There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54).
CONCLUSIONS
A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival.
IMPACT
Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.
Identifiants
pubmed: 34789471
pii: 1055-9965.EPI-21-0977
doi: 10.1158/1055-9965.EPI-21-0977
pmc: PMC9281656
mid: NIHMS1759347
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-452Subventions
Organisme : NCI NIH HHS
ID : R01 CA087538
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA080742
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063678
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA105009
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA080668
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248288
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA095666
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA126841
Pays : United States
Organisme : NCI NIH HHS
ID : N01 PC067010
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA159981
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000056
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA095023
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA113148
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058598
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA138563
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058860
Pays : United States
Organisme : NHGRI NIH HHS
ID : T32 HG000040
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA074850
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : Medical Research Council
ID : MR_UU-12023
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA083918
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA115195
Pays : United States
Organisme : Cancer Research UK
ID : 15601
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA054419
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA122443
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA076016
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES017885
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA017054
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CN025403
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA112523
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA136393
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Int J Gynecol Cancer. 2008 May-Jun;18(3):407-13
pubmed: 17645507
Cancer Causes Control. 2017 May;28(5):487-495
pubmed: 28283879
Cancer Causes Control. 2017 May;28(5):415-428
pubmed: 28342087
Epidemiology. 2000 Mar;11(2):111-7
pubmed: 11021606
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):174-182
pubmed: 29141849
Psychol Methods. 2001 Dec;6(4):330-51
pubmed: 11778676
Mutat Res. 2010 Aug 7;690(1-2):3-11
pubmed: 20223251
Adv Clin Chem. 2009;47:59-93
pubmed: 19634777
Cancer Res. 2008 Apr 1;68(7):2498-506
pubmed: 18381459
J Dent Res. 2012 Feb;91(2):142-9
pubmed: 21876032
BMJ. 1991 Feb 2;302(6771):259-62
pubmed: 1998789
Cancer Res. 2005 Jul 1;65(13):5974-81
pubmed: 15994977
Fertil Steril. 2004 Jul;82(1):186-95
pubmed: 15237010
Int J Cancer. 2009 Mar 15;124(6):1409-15
pubmed: 19065661
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
J Natl Cancer Inst. 2014 Feb;106(2):djt431
pubmed: 24503200
Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):447-51
pubmed: 7549798
Ann N Y Acad Sci. 1999 Jun 22;876:131-43; discussion 144
pubmed: 10415601
Circulation. 2003 Jan 28;107(3):443-7
pubmed: 12551869
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Br J Cancer. 2016 Jun 28;115(1):95-101
pubmed: 27299959
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Gynecol Oncol. 2020 Sep;158(3):702-709
pubmed: 32641237
Breast. 2017 Jun;33:1-7
pubmed: 28254640
Asian Pac J Cancer Prev. ;18(1):11-16
pubmed: 28240000
Br J Cancer. 2015 Sep 1;113(5):817-26
pubmed: 26151456
Cancer Causes Control. 2013 May;24(5):989-1004
pubmed: 23456270
PLoS One. 2010 Apr 08;5(4):e10061
pubmed: 20386703
JAMA. 2004 Apr 14;291(14):1701-12
pubmed: 15082697
JAMA. 2002 Aug 28;288(8):980-7
pubmed: 12190368
J Transl Med. 2012 Feb 27;10:33
pubmed: 22369276
Biomed Res Int. 2017;2017:2984826
pubmed: 29075643
Cancers (Basel). 2018 Jul 30;10(8):
pubmed: 30061485
Br J Cancer. 2016 Nov 22;115(11):1391-1399
pubmed: 27701384
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cancer Prev Res (Phila). 2013 Aug;6(8):811-21
pubmed: 23761272
Cancer Causes Control. 2010 Oct;21(10):1731-41
pubmed: 20559705
Am J Epidemiol. 2017 Jan 1;185(1):8-20
pubmed: 27941069
Int J Cancer. 2017 Jun 1;140(11):2422-2435
pubmed: 28063166
Int J Cancer. 2008 Jan 1;122(1):170-6
pubmed: 17721999
Am J Cardiol. 2001 Oct 1;88(7):825-8
pubmed: 11589863
Endocr Rev. 2007 Aug;28(5):521-74
pubmed: 17640948
PLoS One. 2017 Dec 19;12(12):e0189233
pubmed: 29261726
J Cancer Surviv. 2019 Dec;13(6):956-967
pubmed: 31646463
Int J Cancer. 2006 Dec 15;119(12):2907-15
pubmed: 16998830
Epidemiology. 2016 May;27(3):334-46
pubmed: 26689397
Respir Res. 2002;3:22
pubmed: 12204101
Int J Mol Sci. 2017 Aug 19;18(8):
pubmed: 28825631
Cancer Causes Control. 2012 Dec;23(12):1985-94
pubmed: 23065074
Sci Rep. 2015 Oct 19;5:15224
pubmed: 26477569
Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):103-11
pubmed: 10667470
Am J Cardiol. 2003 Jan 15;91(2):252-4
pubmed: 12521647
Curr Drug Targets Inflamm Allergy. 2005 Dec;4(6):619-25
pubmed: 17305518
J Clin Oncol. 2015 Dec 10;33(35):4138-44
pubmed: 26417001
Gynecol Oncol. 2019 Feb;152(2):259-264
pubmed: 30558974
Cancer Causes Control. 2019 May;30(5):537-547
pubmed: 30905014
Ann Epidemiol. 2011 Mar;21(3):188-96
pubmed: 21109450
Nature. 2019 May;569(7758):723-728
pubmed: 31043742
Lancet Oncol. 2018 Aug;19(8):1107-1116
pubmed: 30029888
Joint Bone Spine. 2013 Jul;80(4):368-73
pubmed: 23352515
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
Int J Cancer. 2020 Dec 15;147(12):3361-3369
pubmed: 32542708
Br J Cancer. 2017 Mar 28;116(7):964-971
pubmed: 28208158
BMC Womens Health. 2011 Sep 23;11:40
pubmed: 21943063
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41
pubmed: 16985038